ArticlePrenatal diagnosis2026
Prenatal Diagnosis and Management of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Imaging Features and First Experience With Maternal Sirolimus Therapy.
Article in Prenatal diagnosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the prenatal diagnosis, evolution, and perinatal management of kaposiform hemangioendothelioma (KHE) complicated by the Kasabach-Merritt phenomenon (KMP), and to report the first documented use of maternal sirolimus therapy (MST) in this setting.
methodsWe retrospectively reviewed four fetuses with a prenatal soft-tissue mass suspected for KHE. Imaging characteristics, fetal complications, perinatal outcomes, and postnatal hematologic data were analyzed. MST was initiated in one severe case with rapidly progressive disease and early fetal compromise.
resultsAll lesions demonstrated infiltrative margins, marked hypervascularity, and T2-hyperintense signal on MRI. Three fetuses showed prenatal signs suggestive of evolving KMP. Two pregnancies were terminated. Among the two liveborn infants, one developed early neonatal KMP requiring urgent sirolimus therapy. All lesions demonstrated infiltrative margins, marked hypervascularity, and T2-hyperintense signal on MRI. Three fetuses showed prenatal signs suggestive of evolving KMP. Two pregnancies were terminated. Among the two liveborn infants, one developed early neonatal KMP requiring urgent sirolimus therapy. In the most recent case, a temporal association was observed between MST initiation and early reduction of tumor infiltration on follow-up MRI. The infant was delivered at 39 weeks and responded to combined sirolimus-steroid therapy.
conclusionPrenatal imaging can strongly suggest KHE and identify early signs of KMP. This series provides preliminary evidence that MST may represent a promising antenatal therapeutic option in selected severe cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.